New Delhi: US President Donald Trump has made a big utterance regarding the import of generic medicines. He has said that heavy tariffs will be imposed on generic drugs imported into America in a phased manner. According to Trump, the purpose of this policy is to bring drug manufacturing when to America and strengthen the domestic pharma industry. However, this visualization is expected to have the biggest impact on India, considering India is the largest supplier of generic medicines to America.
What is Trump's new tariff plan?
Donald Trump said on his social media platform 'Truth Social' that from August 1, 2026, no tariff will be imposed on all generic drugs imported into the US for the first two years. After this, 100% tariff will be workable on these medicines from the third year i.e. 2028. Later it will be increased to 200%. He said that companies are stuff given unbearable time to set up production units in America. Additional whoopee can moreover be taken versus companies that do not do so within the stipulated time.
Why is America taking this step?
Trump says that the purpose of this policy is to promote the production of generic drugs in America and reduce dependence on foreign imports. According to him, this will strengthen the American pharmaceutical industry, create new employment opportunities and make the country's pharmaceutical supply uniting increasingly secure. He moreover clarified that at present there will be no transpiration in the existing policy related to patented and innovative medicines.
How much impact can it have on India?
India is tabbed the 'Pharmacy' of the world and the US market is the largest export destination for Indian pharmaceutical companies. In the financial year 2024-25, India exported medicines worth well-nigh $9.7 billion to the US, which was well-nigh 38 percent of the country's total pharma exports. The share of Indian companies in the quantity of generic medicines sold in the American market is considered to be well-nigh 40 percent. In such a situation, if the proposed tariff is implemented, both the forfeit and competitiveness of Indian pharmaceutical companies may be affected.
Which medicines can have the greatest impact?
Indian companies supply many essential generic medicines to America like upper thoroughbred pressure, diabetes, cancer, mental health, infection and contraceptives. According to reports, a large number of prescriptions written for contraceptive pills in the US during 2024 were for drugs manufactured by Indian companies Glenmark Pharmaceuticals and Lupine. In such a situation, increasing tariff may increase pressure on the unshortened Indian pharma industry including these companies.
Will the effect be visible immediately?
Experts believe that this utterance will not have an firsthand impact, as the proposed tariff will be implemented in a phased manner. The pharmaceutical sector is moreover included in the trade talks once going on between India and America. In such a situation, there remains telescopic for negotiations between the two countries surpassing the final policy is implemented. However, Trump's utterance has definitely increased the concerns of the Indian pharmaceutical industry and investors.
What will happen next?
Now vision are on how the US wardship implements this policy and what consensus is reached regarding the pharma sector in the India-US trade talks. If the proposed 100 to 200 percent tariff is implemented, Indian companies may need to increase production in the US, prefer new strategies or focus increasingly on other global markets.
